22q11.2 Deletion Syndrome: A Comprehensive Disease Characteristics Report

Summary

22q11.2 Deletion Syndrome (22q11.2DS) — historically fragmented into DiGeorge syndrome, velocardiofacial (Shprintzen) syndrome, and conotruncal anomaly face syndrome — is the most common human chromosomal microdeletion syndrome, affecting approximately 1 in 4,000 live births (PMID: 35645294). It is caused by a recurrent hemizygous deletion of chromosome 22q11.2, most commonly a ~3 Mb "typically-deleted region" (TDR) spanning low-copy-repeat blocks LCR22A–D and encompassing ~106 genes (PMID: 32117416). Haploinsufficiency of the T-box transcription factor TBX1 is considered the single greatest contributor to the physical phenotype, disrupting development of the pharyngeal apparatus and neural crest (PMID: 23799583).

The syndrome is a lifelong, incurable, multisystem disorder with extraordinarily variable expressivity. Its cardinal features derive from a developmental failure of the pharyngeal arches and neural crest: conotruncal congenital heart disease (40–50% of patients, and the leading cause of pediatric mortality), thymic hypoplasia with T-cell immunodeficiency, parathyroid hypoplasia with hypocalcemia, palatal/velopharyngeal anomalies, and characteristic craniofacial dysmorphism. Superimposed on these is a heavy neuropsychiatric burden: intellectual disability, a 20–30% lifetime risk of schizophrenia, autism-spectrum traits, ADHD, and a markedly elevated risk of early-onset Parkinson's disease (PMID: 42585902; PMID: 39918054). Genes on the intact homolog (notably COMT Val158Met) and rare damaging variants in chromatin-regulatory modifier genes shape the severity of both cardiac and neurocognitive outcomes.

Inheritance is autosomal dominant, but ~90% of deletions arise de novo through non-allelic homologous recombination between the flanking low-copy repeats; an affected individual has a ~50% chance of transmitting the deletion (PMID: 14708107). Diagnosis relies on chromosomal microarray, FISH, or MLPA, with prenatal cell-free DNA screening now achievable at high positive predictive value when fetal-fraction amplification is used (PMID: 38622914). Management is organ-directed and guideline-based (cardiac surgery, calcium/vitamin D supplementation, immune surveillance and thymus transplantation for the rare complete-athymia subset, and lifelong psychiatric monitoring).

Disease Overview and Identifiers

Section 1 — Disease Information. 22q11.2DS is a contiguous gene deletion syndrome affecting multiple organ systems derived from the embryonic pharyngeal apparatus. It unifies several previously separate clinical entities. The information in this report is drawn from aggregated, disease-level resources (OMIM, Orphanet, consensus clinical practice guidelines, and cohort studies) rather than from individual EHR records.

Resource Identifier
MONDO MONDO:0008644 (22q11.2 deletion syndrome)
OMIM #188400 (DiGeorge syndrome); #192430 (velocardiofacial syndrome)
Orphanet ORPHA:567
ICD-10 D82.1 (DiGeorge syndrome)
ICD-11 LD44.5 / 4A00.1Y (DiGeorge anomaly)
MeSH D004062 (DiGeorge Syndrome) / 22q11 Deletion Syndrome

Common synonyms: DiGeorge syndrome (DGS), velocardiofacial syndrome (VCFS), Shprintzen syndrome, conotruncal anomaly face syndrome (CTAF/Takao syndrome), CATCH-22 (a now-deprecated mnemonic: Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia), and thymic hypoplasia.

Key Findings

Finding 1 — The 22q11.2 microdeletion and TBX1 haploinsufficiency are the molecular cause

The syndrome is caused by a hemizygous 22q11.2 microdeletion. Approximately 85–90% of patients carry the ~3 Mb "typically-deleted region" (TDR) bounded by low-copy repeats LCR22A–LCR22D, producing haploinsufficiency of ~106 genes, including coding RNAs, non-coding RNAs, and pseudogenes (PMID: 32117416). A smaller ~1.5 Mb proximal deletion (LCR22A–B) accounts for most craniofacial phenotypes (PMID: 35645294).

Among the deleted genes, TBX1 — a T-box transcription factor — is the greatest single contributor to the disorder. As the review by Scambler and colleagues states: "Although up to 50 genes may be deleted, it is haploinsufficiency of the transcription factor TBX1 that is thought to make the greatest contribution to the disorder. Mouse embryos are exquisitely sensitive to varying levels of Tbx1 mRNA, and Tbx1 is required in all three germ layers of the embryonic pharyngeal region for normal development" (PMID: 23799583). The dose-sensitivity of the developing embryo to TBX1 is the molecular root of the phenotype.

Finding 2 — Neural crest / pharyngeal apparatus disruption produces the cardinal malformations

TBX1 acts in the pharyngeal ectoderm, endoderm, and mesoderm, and also directs non-cell-autonomous signaling between the pharyngeal surface ectoderm and rostral neural crest. It interacts with the fibroblast growth factor (FGF), retinoic acid, CTNNB1/β-catenin (Wnt), and bone morphogenetic protein (BMP) pathways (PMID: 23799583). Disruption of neural crest development leads directly to the cardinal congenital malformations: "Neural crest development is usually impacted leading to various cardiovascular defects including Tetralogy of Fallot and truncus arteriosus. It can also cause palatal defects, especially velopharyngeal deficiency" (PMID: 40038168).

Finding 3 — 22q11.2DS confers a 20–30% lifetime schizophrenia risk and broad neuropsychiatric burden

22q11.2DS is one of the strongest known genetic risk factors for psychiatric illness: "22q11.2 deletion syndrome (22q11DS) confers a 20-30% lifetime risk of schizophrenia, with negative symptoms associated with poorer outcomes and higher psychosis risk" (PMID: 42585902). Patients show elevated positive/disorganized symptoms, negative-motivational and negative-expressive dimensions, autism-spectrum traits, ADHD, and global neurocognitive impairment. Widespread brain structural alterations are documented across large consortia (ENIGMA-22q).

At the cellular level, genes within the deletion show a strong expression bias toward VIP-expressing, caudal-ganglionic-eminence (CGE)-derived GABAergic interneurons: "genes within 22q11.2 deletions, known to confer a high risk for SCZ, ASD, and cognitive impairment, showed a strong expression bias toward vasoactive intestinal peptide-expressing cells (VIP+) among CGE subtypes" (PMID: 40236134), implicating a specific vulnerable interneuron population.

Finding 4 — The deletion is common (~1 in 4,000 births) and frequently under-recognized

The 22q11.2 deletion "is one of the most common genetic microdeletions, affecting approximately 1 in 4000 live births in humans" (PMID: 35645294). It is a leading genetic cause of conotruncal congenital heart disease: in a cohort of adults with congenital heart disease, "In Tetralogy of Fallot, 4.3% had 22q11.2 deletion, mostly diagnosed in childhood; among those without prior diagnosis, most were neither clinically suspected nor tested in adulthood, suggesting under-recognition" (PMID: 42020136). Under-recognition in adults is a recurrent theme with important implications for surveillance and genetic counseling.

Finding 5 — COMT haploinsufficiency and Val158Met genotype modulate cognition and psychosis

COMT (catechol-O-methyltransferase), which degrades synaptic dopamine, lies within the deleted region. 22q11.2DS samples show "an approximately 50% reduction in COMT mRNA, protein, and enzyme activity levels" (PMID: 23992923). Because only one COMT allele remains, the functional Val158Met (rs4680) polymorphism on the intact allele has an outsized effect. In a cohort of 92 patients, "22q11.2DS subjects with Met allele displayed higher IQ scores in all age groups compared to Val carriers, reaching significance in both adolescents and adults. The Met allele carriers performed better than Val carriers in EF tasks" (PMID: 24853458). A longitudinal imaging study further found that COMT-Met carriers showed greater dorsal prefrontal cortex gray-matter reduction over time, linking COMT genotype to structural brain trajectories predicting psychosis (PMID: 20817203).

Finding 6 — Chromatin-regulatory modifier genes influence conotruncal heart defect risk

Conotruncal CHD occurs in 40–50% of patients, but not all deletion carriers develop it — pointing to modifiers. Whole-genome sequencing of 456 conotruncal-defect cases vs 537 controls (all with 22q11.2DS) identified rare damaging variants in 37 chromatin regulatory genes (including EP400, KAT6A, KMT2C, KMT2D, NSD1, CHD7, PHF21A, EZH2): "we identified 37 chromatin regulatory genes, that may increase risk for conotruncal heart defects in 8.5% of 22q11.2DS cases" (PMID: 37463940). These genes are co-expressed with TBX1 in cardiac progenitor cells and genetically interact with Tbx1 in mice.

Direct experimental confirmation comes from a mouse model: "conditional inactivation of Kmt2d in the Tbx1 lineage in Tbx1-heterozygous mice leads to fully penetrant perinatal lethality and increased incidence of craniofacial dysmorphism, thymus and parathyroid gland hypoplasia, and aortic arch anomalies" (PMID: 42635044). This establishes KMT2D as a bona fide genetic modifier of TBX1 haploinsufficiency.

Finding 7 — Congenital heart disease is the leading cause of pediatric mortality; mouse models recapitulate core features

"Congenital heart diseases (CHDs) and cardiovascular abnormalities are one of the pillars of clinical diagnosis of 22q11.2 deletion syndrome (22q11.2DS) and still represent the main cause of mortality in the affected children" (PMID: 29663641). As survival improves, the adult population has grown, bringing acquired cardiovascular problems and multisystem comorbidity into focus.

Tbx1-haploinsufficient mice recapitulate the syndrome's core features — craniofacial anomalies, thymus/parathyroid hypoplasia, and aortic arch/conotruncal anomalies — and also CNS phenotypes: "In mice, this paraflocculus/flocculus dysplasia is associated with haploinsufficiency of the Tbx1 gene. Tbx1 haploinsufficiency also leads to impaired cerebellar synaptic plasticity and motor learning" (PMID: 39638997).

Finding 8 — Autosomal dominant, mostly de novo (~90%), with ~50% offspring transmission risk

"The majority of deletions are de novo, with 10% or less inherited from an affected parent" (PMID: 14708107). The recurrent deletion arises via non-allelic homologous recombination (NAHR) between the low-copy-repeat blocks LCR22A–D. Inheritance is autosomal dominant — an affected individual has a ~50% chance of transmitting the deletion. Recurrence risk to unaffected parents is low; independent de novo events have been documented even in first cousins, and germline mosaicism is rare.

Finding 9 — Diagnosis by CMA/FISH/MLPA; prenatal cfDNA with fetal-fraction amplification achieves high PPV

The small size of the microdeletion makes standard prenatal cell-free DNA (cfDNA) screening technically challenging. A cfDNA assay incorporating fetal-fraction amplification screened 379,428 patients; of 76 screen-positives for de novo 22q11.2 microdeletion, "22 (29.7%) had diagnostic testing results available, and all 22 cases were confirmed as true positives, for a PPV of 100% (95% CI 84.6%-100%)" (PMID: 38622914). A multiplex digital-PCR cffDNA assay achieved 73.3% sensitivity / 96.5% specificity (PMID: 37684689). Current professional guidance (SMFM Consult Series #74, 2025) is cautious: "we do not recommend routine general population screening for any microdeletion condition. Patients who choose to undergo cfDNA screening for 22q11.2 deletion specifically should do so only after appropriate pretest counseling" (PMID: 42597105).

Finding 10 — Thymic hypoplasia causes T-cell immunodeficiency, autoimmunity, and atopy; complete athymia requires thymus transplant

Impaired thymus development is central to the immune phenotype: "This thymic dysfunction impairs T-cell development and maturation, leading to a spectrum of T-cell lymphopenia, a restricted T-cell receptor repertoire and defects relating to regulatory T cells. Consequently, patients exhibit increased susceptibility to recurrent infections, particularly of the respiratory tract and a higher prevalence of autoimmune conditions and atopic diseases" (PMID: 41730804). Most patients have partial DiGeorge — mild-to-moderate T-cell lymphopenia that tends to improve with age. A small subset (<1%) have complete athymia, for which "Thymus implantation is the definitive treatment" (PMID: 41902846); allogeneic hematopoietic cell transplantation is an alternative. Impaired T-cell surveillance can permit EBV-associated complications, including chronic facial granulomatous dermatitis and, rarely, early Hodgkin lymphoma (PMID: 42114650; PMID: 41942950).

Finding 11 — Parathyroid/thyroid dysgenesis causes hypocalcemia and thyroid dysfunction; hemizygosity can unmask recessive disease

"Individuals may also present with hypocalcemia and thyroid dysfunction due to impaired parathyroid gland formation and thyroid dysgenesis, respectively" (PMID: 40038168). Neonatal hypocalcemia may present with seizures or tetany and can be refractory to conventional therapy (PMID: 40866089). Uniquely, hemizygosity of the region can unmask recessive disease from a variant on the non-deleted homolog: "Variations in genes on the non-deleted homologous chromosome in the critical 22q11.2 region can further influence phenotypes by revealing recessive diseases. This effect has been documented for several genes in this area, such as SNAP29 and GP1BB" (PMID: 40038168) — e.g., CEDNIK syndrome (SNAP29) and Bernard-Soulier syndrome (GP1BB).

Finding 12 — 22q11.2DS markedly elevates the risk of early-onset Parkinson's disease

In a multicenter study of 856 adults with 22q11.2DS: "PD was present in 1.8% (95% CI: 0.9-2.6%) of the sample, 3.4% (95% CI: 2.2-4.6%) when including uncertain PD (clinical diagnosis or suspicion, but not meeting all criteria), and 14.0% (95% CI: 6.9-21.0%) of those aged ≥50 years. Median age at motor onset was 45 (range 20-66) years" (PMID: 39918054). This early onset (median ~45 years vs ~60 in idiopathic PD) has prompted proposals for periodic motor evaluation from age 40. A candidate biomarker exists: salivary monomeric α-synuclein is reduced in parkinsonian 22q11.2DS patients (AUC 0.86 discriminating Park+ from Park−) (PMID: 38661486). A Del(3.0 Mb)/+ mouse shows "reduced axon innervation of dopaminergic neurons into the prefrontal cortex" (PMID: 37238632), a dopaminergic deficit relevant to both parkinsonian and psychiatric phenotypes.

Detailed Section Coverage

2. Etiology

3. Phenotypes

Phenotype Type Frequency Onset HPO term
Conotruncal congenital heart disease (TOF, truncus arteriosus, IAA, VSD) Physical malformation 40–50% Congenital HP:0001636 / HP:0001671
Velopharyngeal insufficiency / cleft palate Physical/functional ~65–70% (palatal) Congenital/childhood HP:0000220 / HP:0000175
T-cell immunodeficiency / recurrent infection Laboratory/clinical ~75% (mostly mild) Neonatal/infancy HP:0005387 / HP:0002719
Hypocalcemia / hypoparathyroidism Laboratory ~50–65% (often neonatal, may recur) Neonatal HP:0002917 / HP:0000829
Intellectual disability / learning disability Behavioral/cognitive Majority; borderline-mild Childhood HP:0001249
Schizophrenia / psychosis Behavioral 20–30% lifetime Adolescence/adulthood HP:0100753
Autism spectrum / ADHD Behavioral Common Childhood HP:0000717 / HP:0007018
Parkinsonism / early-onset PD Clinical sign 1.8% overall; 14% if ≥50 y Adult (median 45 y) HP:0001300
Characteristic craniofacial dysmorphism Physical Common Congenital HP:0001999
Chronic otitis media / hearing loss / airway anomalies Clinical High ENT burden Childhood HP:0000388 / HP:0000365

Expressivity is highly variable even within families; severity ranges from mild to life-threatening. Quality-of-life impact is substantial and lifelong, spanning cardiac, immune, endocrine, cognitive, psychiatric, speech, and ENT domains, requiring multidisciplinary care and structured pediatric-to-adult transition (PMID: 40223294; PMID: 41800660).

4. Genetic / Molecular Information

5. Environmental Information

No infectious agent or environmental toxin causes 22q11.2DS; it is a constitutional genetic disorder. Secondary/opportunistic infections (viral, especially EBV; recurrent respiratory pathogens) arise as consequences of T-cell immunodeficiency rather than causes of the syndrome (PMID: 41730804; PMID: 41942950). Lifestyle factors do not contribute to etiology.

6. Mechanism / Pathophysiology — Ordered Causal Chain

1. Recurrent NAHR between LCR22A–D low-copy repeats
      → results in a de novo ~3 Mb hemizygous 22q11.2 deletion (~106 genes)      [PMID 32117416, 14708107]
2. Deletion → haploinsufficiency of dosage-sensitive genes, chiefly TBX1        [PMID 23799583]
3. Reduced TBX1 dosage in pharyngeal ecto/endo/mesoderm
      → dysregulated FGF, retinoic-acid, BMP, and WNT/β-catenin signaling        [PMID 23799583]
4. Aberrant signaling to the rostral neural crest (non-cell-autonomous)
      → defective pharyngeal-arch and neural-crest development                    [PMID 23799583, 40038168]
      ├── BRANCH A → 4th-arch artery / outflow-tract defects
      │        → conotruncal CHD (TOF, truncus, IAA-B)                            [PMID 40038168, 29663641]
      │        → leading cause of pediatric mortality
      ├── BRANCH B → 3rd/4th pouch (thymus) hypoplasia
      │        → impaired T-cell development, restricted TCR repertoire, Treg defect
      │        → immunodeficiency, autoimmunity, atopy, EBV complications         [PMID 41730804]
      ├── BRANCH C → parathyroid (3rd/4th pouch) + thyroid dysgenesis
      │        → hypoparathyroidism → hypocalcemia (seizures/tetany)              [PMID 40038168]
      ├── BRANCH D → palatal / velopharyngeal + craniofacial maldevelopment
      │        → cleft palate, VPI, dysmorphism, ENT disease                      [PMID 40038168, 35645294]
      └── BRANCH E (neuro) → COMT/DGCR8/PRODH dosage + interneuron vulnerability
               → ~50% ↓ COMT activity → altered prefrontal dopamine              [PMID 23992923]
               → VIP+ CGE interneuron bias; reduced DA innervation of PFC
               → intellectual disability, 20–30% schizophrenia, early-onset PD    [PMID 40236134, 39918054, 37238632]
5. Genetic modifiers (chromatin regulators e.g. KMT2D; COMT Val158Met;
   non-deleted-homolog variants) tune severity/penetrance of each branch         [PMID 37463940, 42635044, 24853458]

Upstream vs downstream: The deletion and TBX1 haploinsufficiency are the most upstream events; pharyngeal/neural-crest signaling failure is the key developmental node from which the organ-specific branches diverge. The neuropsychiatric branch is partly independent, driven by dosage of COMT/DGCR8/PRODH and cortical interneuron vulnerability rather than by TBX1 alone — consistent with evidence that the physical phenotype is largely TBX1-attributable while the brain phenotype is multigenic (PMID: 34552467). Changes in brain metabolism from deleted metabolic genes may further contribute to variable brain phenotypes (PMID: 39567195).

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population

10. Diagnostics

11. Outcome / Prognosis

12. Treatment

No cure exists; management is organ-directed and multidisciplinary, per 22q11.2 Society consensus guidelines for children (PMID: 36729053) and adults (PMID: 36729052).

Domain Intervention NCIT-type term
Cardiac Surgical repair of conotruncal defects Cardiac surgery
Endocrine Calcium + active vitamin D (calcitriol); teriparatide for refractory hypocalcemia (PMID: 40866089) Calcium/vitamin D supplementation
Immune Infection prophylaxis, irradiated/CMV-safe blood, live-vaccine caution; cultured thymus tissue implantation for complete athymia; allogeneic HCT alternative (PMID: 41902846; PMID: 39303894) Thymus transplantation
Psychiatric Antipsychotics, standard psychiatric care; caution given COMT dosage Antipsychotic therapy
ENT/speech Palatoplasty, VPI surgery, otologic/airway management, speech therapy (PMID: 41800660) Speech therapy / palatoplasty
Supportive Developmental, educational, and rehabilitative services Rehabilitation therapy

Immunological management is standardized in dedicated guidelines (PMID: 36648576). Pharmacogenomic caution around COMT-metabolized drugs is biologically plausible but not yet guideline-mandated. No approved gene/RNA therapy exists; mouse studies have shown pharmacological rescue of single-gene cortical phenotypes as proof of concept (PMID: 34552467).

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Interpretation

The unifying interpretation is that a single upstream lesion — the 22q11.2 deletion — produces a fan of downstream phenotypes through two partly separable routes. The TBX1-dependent route explains the "physical" DiGeorge/VCFS features: reduced TBX1 dosage perturbs FGF/RA/BMP/WNT signaling in the pharyngeal apparatus and its cross-talk with neural crest, and the affected pharyngeal pouches/arches map cleanly onto the affected organs (outflow tract, thymus, parathyroid, palate, ear/airway). The TBX1-independent, multigenic route explains the "brain" phenotypes: dosage of COMT, DGCR8, PRODH and others, together with intrinsic vulnerability of VIP+ CGE-derived interneurons and reduced prefrontal dopaminergic innervation, drives intellectual disability, the 20–30% schizophrenia risk, and early-onset parkinsonism. Overlaid on both routes is a modifier layer — chromatin regulators (KMT2D and network), COMT Val158Met, and variants unmasked on the intact homolog — that converts uniform haploinsufficiency into the syndrome's hallmark variable expressivity. This two-route-plus-modifier architecture reconciles why physical features are largely TBX1-attributable and highly recurrent across models, while neuropsychiatric outcomes are heterogeneous and only partially modeled in mice.

Evidence Base

PMID Contribution Evidence type
23799583 TBX1 as principal driver; pharyngeal/neural-crest signaling Human/model review
32117416 Deletion size (~3 Mb), ~106 genes Review
35645294 Prevalence ~1/4000; deletion sizes; craniofacial genetics Review
40038168 Neural crest → CHD/palate; hypocalcemia/thyroid; recessive unmasking Review
42585902 20–30% schizophrenia risk; negative symptoms Human cohort
40236134 VIP+ CGE interneuron vulnerability Genomic/cellular
42020136 4.3% of TOF carry deletion; adult under-recognition Human cohort
23992923 ~50% ↓ COMT mRNA/protein/activity; psychosis haplotypes Human/molecular
24853458 COMT Val158Met modifies IQ/EF (n=92) Human cohort
37463940 37 chromatin regulators modify CHD (8.5%) Human WGS
42635044 Kmt2d modifies Tbx1 haploinsufficiency Mouse model
29663641 CHD as leading pediatric mortality Review
39638997 Tbx1 cerebellar/motor phenotype Mouse model
14708107 ~90% de novo; independent de novo events Human case
38622914 cfDNA fetal-fraction amplification PPV 100% Human screening
42597105 SMFM cfDNA guidance Guideline
41730804 Thymic dysfunction → immunodeficiency/autoimmunity/atopy Review
41902846 Thymus implantation for athymia Human cohort
39918054 PD prevalence; onset median 45 y (n=856) Human cohort
37238632 Reduced PFC dopaminergic innervation Mouse model

Limitations and Knowledge Gaps

  1. No primary data analysis was performed — this report synthesizes literature and curated database identifiers; frequency figures are approximate and drawn from heterogeneous cohorts.
  2. Ontology IDs (MONDO, OMIM, HPO, GO, CL, UBERON, CHEBI, NCIT) were assigned from domain knowledge, not programmatically verified against current ontology releases; they should be cross-checked before database ingestion.
  3. Frequency/penetrance estimates vary by ascertainment (cardiac clinics vs psychiatric vs population), and adult under-recognition biases prevalence downward.
  4. Neuropsychiatric mechanism remains incompletely resolved — the relative contributions of COMT, DGCR8, PRODH, interneuron biology, and metabolic changes are not fully quantified, and human mechanistic evidence is largely correlational.
  5. Biomarkers (salivary α-synuclein, mandibular trabecular FD) are exploratory, based on small samples (n≈10–11 per group) and require validation.
  6. Treatment evidence base is limited — consensus guidelines are largely expert-opinion given the rarity and heterogeneity of the syndrome; no disease-modifying therapy exists.

Proposed Follow-up Experiments / Actions

  1. Verify all ontology term IDs against current MONDO/HPO/GO/CL/UBERON/NCIT releases before knowledge-base ingestion.
  2. Assemble a per-phenotype frequency table with confidence intervals from the largest available registries (22q11.2 Society, ENIGMA-22q, International 22q11.2 Brain Behavior Consortium) rather than narrative-review estimates.
  3. Systematically catalog modifier variants (chromatin regulators, COMT/PRODH, non-deleted-homolog variants) with effect sizes for genotype–phenotype annotation.
  4. Validate candidate biomarkers — salivary α-synuclein for parkinsonism and imaging-derived cerebellar/cortical deviation scores for cognitive prognosis — in larger prospective cohorts.
  5. Curate the mouse-model phenotype-recapitulation matrix (Tbx1, Df(16)A, Del(3.0Mb), Kmt2d compounds) mapping each mouse phenotype to its human HPO counterpart with recapitulation confidence.
  6. Track emerging trials (ClinicalTrials.gov) for thymus tissue implantation, psychiatric interventions, and any gene/RNA-directed approaches, capturing NCT identifiers.